EXOC7 and neoplasm: We further found that cisplatin-induced autophagy-lysosome degradation of the Exo70 protein was hampered in acquired cisplatin-resistant EOC cells (Figure 4 and Figure 5), suggesting that testing the half-life of the Exo70 protein under cisplatin treatment in patient-derived tumor cells could be a promising approach allowing us to predict whether an EOC patient could still respond to platinum-based chemotherapy after relapse.